弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展

doi:10.11904/j.issn.1002-3070.2022.03.012

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (3): 259-262.doi: 10.11904/j.issn.1002-3070.2022.03.012

弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展

郑艳丽综述, 贺建霞审校

山西医科大学第五临床医学院血液科(太原 030001)

收稿日期:2022-02-26 修回日期:2022-04-19 出版日期:2022-06-28 发布日期:2022-06-28
通讯作者: 贺建霞,E-mail:hejianxia125@163.com
作者简介:郑艳丽,女,(1996-),硕士研究生,从事恶性血液病基础与临床的研究。
基金资助:
山西省自然科学基金(编号:201901D111435)

Research progress of DNA methylation in diffuse large B-cell lymphoma

ZHENG Yanli, HE Jianxia

Department of Hematology,The Fifth Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China

Received:2022-02-26 Revised:2022-04-19 Online:2022-06-28 Published:2022-06-28

摘要/Abstract

摘要： 弥漫大B细胞淋巴瘤(DLBCL)异质性较高,具有不同的临床和病理特征,是成人淋巴瘤的一种常见类型。尽管一部分DLBCL已经可以治愈,但难治和复发患者的治疗仍然具有挑战性。近年来,DNA甲基化等表观遗传修饰成为DLBCL的研究热点。调控甲基化修饰的基因突变及抑癌基因甲基化修饰在DLBCL发病及预后中起到关键作用。本文对DLBCL的DNA甲基化研究进展进行综述。

关键词: 弥漫大B细胞淋巴瘤, DNA甲基化, 表观遗传学, 靶向治疗

Abstract: Diffuse large B-cell lymphoma(DLBCL)is a common type of adult lymphoma with high heterogeneity and different clinical and pathological features.Although some DLBCLs are curable,the management of refractory and relapsed patients remains challenging.In recent years,epigenetic modifications such as DNA methylation have become a research hotspot of DLBCL.Gene mutations regulating methylation modification and methylation modification of tumor suppressor genes play a key role in the pathogenesis and prognosis of DLBCL.This paper reviews the research progress of DNA methylation in DLBCL.

Key words: Diffuse large B-cell lymphoma, DNA methylation, Epigenetics, Targeted therapy

中图分类号:

R733.1

郑艳丽, 贺建霞. 弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(3): 259-262.

ZHENG Yanli, HE Jianxia. Research progress of DNA methylation in diffuse large B-cell lymphoma[J]. Journal of Practical Oncology, 2022, 36(3): 259-262.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.03.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I3/259

参考文献

1 Hernández VI,Labreche K,Benazra M,et al.Tracking the genetic susceptibility background of B-cell non-hodgkin′s lymphomas from genome-wide association studies[J].Int J Mol Sci,2020,22(1):122.
2 李丽燕,付蓉.复发难治性弥漫大B细胞淋巴瘤靶向药物治疗进展[J].中国肿瘤临床,2019,46(11):581-585.
3 Licht JD,Bennett RL.Leveraging epigenetics to enhance the efficacy of immunotherapy[J].Clin Epigenetics,2021,13(1):115.
4 Wedge E,Hansen JW,Garde C,et al.Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma[J].Am J Hematol,2017,92(7):689-694.
5 Amara K,Ziadi S,Hachana M,et al.DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas[J].Cancer Sci,2010,101(7):1722-1730.
6 周怡,王鑫,安依涵,等.索拉非尼联合地西他滨协同作用诱导弥漫大B细胞淋巴瘤凋亡的机制研究[J].中国实验血液学杂志,2020,28(1):146-152.
7 马咪静.地西他滨治疗弥漫大B细胞淋巴瘤的临床疗效观察及生物学活性研究[D].郑州:郑州大学,2019.
8 Clozel T,Yang S,Elstrom RL,et al.Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma[J].Cancer Discov,2013,3(9):1002-1019.
9 Yin X,Xu Y.Structure and function of TET enzymes[J].Adv Exp Med Biol,2016,945:275-302.
10 Cimmino L,Dawlaty MM,Ndiaye-Lobry D,et al.TET1 is a tumor suppressor of hematopoietic malignancy[J].Nat Immunol,2015,16(6):653-662.
11 Quivoron C,Couronné L,Della Valle V,et al.TET2 Inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis[J].Cancer Cell,2011,20(1):25-38.
12 Vipul S,Daniela S,Zhen D,et al.TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures[J].Nat Immunol 2022,23(1):99-108.
13 López-Moyado IF,Tsagaratou A,Yuita H,et al.Paradoxical association of TET loss of function with genome-wide DNA hypomethylation[J].Proc Natl Acad Sci U S A,2019,116(34):16933-16942.
14 Narayan G,Xie D,Freddy AJ,et al.PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis[J].Genes Chromosomes Cancer,2013,52(11):1030-1041.
15 Ying J,Gao Z,Li H,et al.Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies[J].Br J Haematol,2007,136(6):829-832.
16 Shi D,Murty VV,Gu W,et al.PCDH10,a novel p53 transcriptional target in regulating cell migration[J].Cell Cycle,2015,14(6):857-866.
17 Huang W,Xue X,Shan L,et al.Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma[J].BMC Cancer,2017,17(1):815.
18 薛伍君.弥漫大B细胞淋巴瘤PCDH10基因启动子甲基化状态及其临床意义[D].新乡:新乡医学院,2021.
19 Caiado F,Maia-Silva D,Jardim C,et al.Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection[J].Nat Commun,2019,10(1):4986.
20 Dan H,Zhang S,Zhou Y,et al.DNA methyltransferase inhibitors:catalysts for antitumour immune responses[J].Onco Targets Ther,2019,12:10903-10916.
21 Wright GW,Huang DW,Phelan JD,et al.A Probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications[J].Cancer Cell,2020,37(4):551-568.
22 Chen S,Wang Q,Yu H,et al.Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway[J].Nat Commun,2020,11(1):3856.

[1]	陈素, 隋红. 抗HER2治疗在转移性结直肠癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(3): 288-292.
[2]	吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.
[3]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[4]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[5]	杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.
[6]	宋家羽, 冯越, 王棹, 张云艳. 外泌体与妇科恶性肿瘤相关性的最新研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 571-575.
[7]	邓俊, 袁媛, 罗璇, 谭惜颜, 于恩浩, 刘科, 吴崢, 周菊梅, 朱苏雨. 化放疗模式下早期弥漫大B细胞淋巴瘤缩小放疗野对生存预后的影响[J]. 实用肿瘤学杂志, 2020, 34(3): 237-243.
[8]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[9]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[10]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[11]	左志博, 郭志琴, 王振, 杨宏杰, 邬万新. Semaphorin 3F在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 88-92.
[12]	张谊微, 石晶, 刘宇鹏, 曹丽明, 胡付兰, 赵亚双. 外周血USP1基因甲基化与大肠癌预后风险的关系[J]. 实用肿瘤学杂志, 2019, 33(5): 420-424.
[13]	张玫茵娄阁. N6-甲基腺嘌呤与癌症的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 357-360.
[14]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[15]	李悦, 徐可, 韩增祥, 孙敏, 樊国华综述, 张勇审校. 结肠癌中肿瘤相关巨噬细胞的作用及靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 450-454.

弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展

Research progress of DNA methylation in diffuse large B-cell lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价